Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-002 vs Latanoprost in Glaucoma/OHT (CLEAR)
NCT05165290Phase 3Unknown
- Sponsor
- TearClear
- Start
- Nov 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of latanoprost ophthalmic solution 0.005% (TearClear TC-002) in open-angle glaucoma (OAG), ocular hypertension, sponsored by TearClear. Status: unknown.
02
Drugs
latanoprost ophthalmic solution 0.005% (TearClear TC-002)
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT05165290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05165290.